截止2020年09月29日22時(shí)08分iShares Diversified Alternatives（ALT）最新價(jià)12.3300，漲跌額0.0300，漲跌幅0.24%，昨收12.3000，今開(kāi)12.1700，最高12.3800，最低11.9500，成交量190296手。

　　iShares Diversified Alternatives（ALT）2018年01月01日至2018年12月31日Research grants and contracts金額（USD）1031.14萬(wàn)，比率99.81%。

　　iShares Diversified Alternatives（ALT）主要指標(biāo)（幣種：美元）：截止2020年03月31日iShares Diversified Alternatives（ALT）市盈率（TTM）-3.63602394646871，市凈率（MRQ）3.55223347030621，每股收益（TTM）-1.10922876825219，每股凈資產(chǎn)2.08319640638995，每股股息（USD）--，周息率--%，收入總額221.27萬(wàn)，收入總額同比-25.1353366770515%，歸母凈利潤(rùn)-388.56萬(wàn)，歸母凈利潤(rùn)同比-85.2685778803856%，毛利率100%，凈利率-175.607155801932%，總股本2011.17萬(wàn)，總市值（USD）1.49億。

　　公司介紹： Altimmune, Inc. is a clinical-stage immunotherapeutics company focused on the development of products to stimulate robust and durable immune responses for the prevention and treatment of disease and on the development of two next-generation anthrax vaccines that are intended to improve protection and safety while having favorable dosage and storage requirements compared to other anthrax vaccines. The company has two proprietary platform technologies, RespirVec and Densigen, each of which has been shown to activate the immune system in distinctly different ways than traditional vaccines.

　　本站數(shù)據(jù)均為參考數(shù)據(jù)，不具備市場(chǎng)交易依據(jù)。